If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.00    0.00 (0.00%)
Bid:
13.50
Ask:
14.50
Spread: 1.00 (7.407%)
Market Cap: £11.55m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Grant of Options

7 Apr 2016 07:00

RNS Number : 4272U
Frontier IP Group plc
07 April 2016
 

 

AIM: FIPP

7 April 2016

 

FRONTIER IP GROUP PLC

("Frontier IP" or "the Company")

 

Grant of Options

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that its Board has granted options over ordinary shares of 10p each in the Company to the directors below.

Options granted

7 April 2016

Total options

following grant

 

Neil Crabb

350,000

935,000

Jacqueline McKay

150,000

400,000

James Fish

150,000

400,000

David Cairns

75,000

325,000

 

All options are awarded under the Company's Share Option Scheme, the Frontier IP Group plc Employee Share Option Scheme 2011. The options have been awarded at an exercise price of 26.63 pence per share (the closing price of the ordinary shares on 6 April 2016) and the exercise period commences on the third anniversary of the date of grant and expires on the day preceding the tenth anniversary thereof.

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

David Foreman / Catherine Leftley, Corporate Finance

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab

(Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

 

 

Notes to Editor:

 

Frontier IP Group plc

www.frontierip.co.uk.

 

Frontier IP specialises in assisting institutions and companies in the commercialisation and

exploitation of their intellectual property. It establishes formal and informal relationships with

sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spinout companies by taking an active involvement in the commercialisation and funding of these businesses.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSSUFMMFMSELL
Date   Source Headline
30th Jun 20265:00 pmRNSTotal Voting Rights
26th Jun 202610:03 amRNSHolding(s) in Company
25th Jun 20262:44 pmRNSHolding(s) in Company
25th Jun 20267:00 amRNSHolding(s) in Company
24th Jun 20267:00 amRNS-RPortfolio news: Investment in Fieldwork Robotics
23rd Jun 20267:00 amRNSPosting of Circular and Notice of General Meeting
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.